News

The Food and Drug Administration (FDA) has cleared Lumipulse G for U.S. commercialization as the first blood-based test that ...
The Food and Drug Administration cleared a new kind of test for Alzheimer’s disease designed to be more accessible and less ...
The FDA has cleared the first-ever blood test for early Alzheimer's detection, which the agency says reduces the need for ...
The Food and Drug Administration (FDA) announced Friday it had cleared a new test to help diagnose adults with Alzheimer’s ...
The FDA has approved the Lumipulse Plasma Ratio test, a groundbreaking blood test for early dementia detection. This less ...
Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of ...
The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...
The U.S. Food and Drug Administration on Friday approved a new blood test for the early detection of Alzheimer's disease in ...
(Reuters) -The U.S. Food and Drug Administration said on Friday it has cleared Fujirebio Diagnostics' blood test to diagnose ...
Today, the FDA's approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, marking a pivotal moment in the fight against ...
The first in vitro diagnostic device that uses blood samples to detect Alzheimer disease has been granted marketing clearance ...
The Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio is for the early detection of amyloid plaques associated with Alzheimer’s disease in symptomatic adults 55 years and older.